Jarvik Heart Announces FDA Approval of the Jarvik 2000 Destination Therapy Trial

 

August 17, 2012

August 17, 2012 — Jarvik Heart Inc. announced U.S. Food and Drug Administration (FDA) approval of its pivotal trial for evaluation of the Jarvik 2000 heart for destination therapy (DT), named RELIVE (Randomized Evaluation of Long-term Intraventricular VAD [ventricular assist device] Effectiveness).

Use of the device for DT means that it will provide long-term, permanent support to end-stage congestive heart failure patients who are not candidates for heart transplant. The DT approval permits 50 medical centers to participate in the study. Each medical center may begin enrolling patients immediately upon approval by their institutional review board.

Jarvik Heart recently completed enrollment and follow-up to outcome of its 150-patient Bridge-to-Transplant (BTT) study. Patients who received the most recent Jarvik 2000 model, using patented cone bearings, show a substantial improvement in the primary endpoint compared to the pin-bearing design used earlier in the BTT study. The CAP approval permits 25 patients to receive the Jarvik 2000 over the next year at 10 centers that have previously participated in the BTT study.

The DT trial will randomize up to 350 study subjects to either the treatment group, in which patients receive the Jarvik 2000 intraventricular heart assist device, or the control group, in which patients receive the HeartMate II left ventricular assist device (LVAD), the most widely used FDA-approved LVAD for DT.

Patients will be followed for two years to assess primary endpoint success, generally defined as survival free of disabling complications. If the data analysis at two years, or at a prior interim analysis, establishes non-inferiority of the Jarvik 2000 compared to the control, the trial will be judged successful. The patients will also be followed for another year and the rates of serious infection related to the power cable and pump pocket will be analyzed for the three years since implantation. Regarding device-related infection, the analysis is designed to determine if the Jarvik 2000, which uses a unique behind-the-ear power cable and has no pump pocket, is superior to the HeartMate II, which uses an abdominal cable and has an abdominal pump pocket. All DT patients will receive the latest model Jarvik 2000 with cone bearings and the behind-the-ear cable.

The Jarvik 2000 has been used to treat late-stage heart failure in more than 500 patients in the United States, Europe and Asia. The Jarvik 2000 model with the behind-the-ear connector has supported more than 200 patients in Europe for DT, including the longest survival of any heart assist device patient in the world, 7½ years.

The Bridge-to-Transplant model of the Jarvik 2000 has a power cable that exits the abdominal wall — the same position used with the HeartMate II and HeartWare VADs. The behind-the-ear cable, which will be used in the DT study, may have significant quality-of-life advantages over abdominal cables. It requires practically no care of the cable exit site and, unlike abdominal cables, does not require frequent redressing with sterile bandages that may require expensive home nursing. Jarvik 2000 patients with the behind-the-ear connector may shower and bathe normally and can even go swimming. In Europe, these patients have had low rates of infection, and there have been no failures of the internal cables and no mechanical failures of the Jarvik 2000 blood pump or its bearings. Long-term bench durability tests project high reliability of the device for ten years or more.

For more information: www.jarvikheart.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.